Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

The Debate Over Early Screening for Pancreatic Cancer Continues

March 8th 2019

Higher costs associated with advanced stage pancreatic cancer, are potentially avoidable with screening and earlier treatment. However, the US Preventive Services Task Force in an ongoing draft review has reaffirmed its stance against screening in asymptomatic individuals.

Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic Cancer

March 8th 2019

Niharika B. Mettu, MD, PhD, assistant professor medicine, Duke Cancer Institute, discusses the potential of CPI-613 in the treatment of patients with metastatic pancreatic cancer.

Higher Incidence, New Therapies Add to Cost of Treating Advanced Pancreatic Cancer

March 7th 2019

Pancreatic cancer is one of the few cancers that is on the rise, and this means that the overall cost of treating this disease is also climbing.

Dr. Weinberg on Broad Molecular Profiling in GI Cancers

March 7th 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal cancers.

Gastrointestinal Cancer Research Abounds in Washington, DC

March 6th 2019

George P. Kim, MD, discusses areas of active investigation in the Washington, DC, area.

Pivotal Trials Lead to Significant Implications in Gastric/GEJ Cancer

March 6th 2019

Timothy L. Cannon, MD, discusses how pivotal clinical trials have impacted the gastric cancer treatment landscape.

Expert Discusses Frontline Standards, Dosing, and Novel Agents in Pancreatic Cancer

March 6th 2019

Benjamin Weinberg, MD, discusses frontline standards of care in metastatic pancreatic cancer and highlights emerging agents targeting the stroma.

Following Encouraging Therapeutic Advances, Focus in NETs Turns to Sequencing

March 6th 2019

Ana Maria Cristina De Jesus-Acosta, MD, discusses somatostatin analogs and peptide receptor radionucleotide therapy, and spoke to the discussion regarding the optimal sequence of therapy in patients with neuroendocrine tumors.

Dr. Marshall on Personalized Chemotherapy in CRC

March 5th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

HCC Armamentarium Expands, With Promising Agents on the Horizon

March 5th 2019

Aiwu Ruth He, MD, PhD, discusses the newly crowded treatment landscape of hepatocellular carcinoma and highlights next steps for research.

Management of Metastatic CRC Rooted in Molecular Subsets

March 5th 2019

John L. Marshall, MD, discusses the current and future scope of metastatic colorectal cancer.

Dr. Katz on Preoperative Chemoradiation in Localized Pancreatic Cancer

March 5th 2019

Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses preoperative chemoradiation for the treatment of patients with localized pancreatic cancer.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Immunotherapy, Chemo Approaches Continue to Build in CRC and Pancreatic Cancer

March 5th 2019

Douglas A. Nelson, MD, discusses key advances made in the treatment of patients with colorectal cancer and pancreatic cancer, and sheds light on remaining challenges in these paradigms.

Younger Patients With CRC Misdiagnosed, Diagnosed at Later Stages

February 28th 2019

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

Headway Made in GI Cancer Treatment, But Progress Needed

February 28th 2019

Brandon Smaglo, MD, highlights investigational treatment approaches for patients with gastric cancer and calls for further research in the adjuvant setting to move the needle forward.

Frontline Olaparib Maintenance Improves PFS in BRCA+ Pancreatic Cancer

February 26th 2019

Frontline maintenance therapy with olaparib significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial.

FOLFIRINOX Should Remain Adjuvant Standard for Resectable Pancreatic Cancer

February 26th 2019

Matthew H.G. Katz, MD, FACS, highlights pivotal trials in pancreatic cancer and how these data are shifting the treatment paradigm for these patients.

Dr. Overman Discusses ReDOS Study in mCRC

February 26th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Dr. Weinberg Discusses the Use of FOLFIRINOX in Older Patients With Metastatic Pancreatic Cancer

February 26th 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the use of FOLFIRINOX in older patients with metastatic pancreatic cancer.